Acute amivantamab-induced myocardial injury in a patient with epidermal growth factor receptor-mutant lung cancer: a first case report.

ABSTRACT:

Background

Amivantamab, a bispecific antibody against epidermal growth factor receptor and mesenchymal-epithelial transition receptors, has been approved for certain types of non-small cell lung cancer; however, it is known to cause severe adverse events. The management of such adverse events is necessary for maintaining the therapeutic efficacy of amivantamab. The frequency of cardiotoxicity caused by amivantamab is low, despite its association with a high incidence of severe adverse events. Most of the adverse events are cardiovascular events caused by thrombosis. No reports of amivantamab-induced myocardial injury have been published.

Case presentation

We present the first case of drug-induced myocardial injury, detected with tachycardia but not associated with any cardio

SUBMITTER: Kaneko S 

PROVIDER: S-EPMC12722926 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature